Latest Regenerx Biopharmaceuticals Inc (RGRX) Headlines
RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements
Business Wire - Fri Mar 07, 6:57AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) ("the Company" or "RegeneRx") today announced that it has entered into two product license agreements with Digital Aria Co., Ltd., headquartered in Gyeonggi-do, Korea, for Digital Aria to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. Digital Aria will also make an equity investment into RegeneRx of $2.35 million enabling RegeneRx to move forward with its ophthalmic clinical program, and retains a 10-month option to purchase additional common stock for $825,000.
RegeneRx Biopharmaceuticals wins patent for Thymosin beta 4 for treating Dry Eye Syndrome in Israel
M2 - Tue Feb 25, 5:44AM CST
Biopharmaceutical company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Monday the receipt of patent for Thymosin beta 4 in Israel.
RegeneRx Receives Israeli Patent for Treatment of Dry Eye Syndrome
Business Wire - Mon Feb 24, 9:00AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received an Israeli patent for the treatment of Dry Eye Syndrome using Thymosin beta 4 (TB4) and various fragments of TB4, as well as other analogues and derivatives. The patent will expire in 2026.
RegeneRx Biopharmaceuticals Inc awarded patent allowance in the US for neuro and muscular degenerative diseases
M2 - Fri Jan 17, 10:38AM CST
RegeneRx Biopharmaceuticals Inc (RGRX) revealed on Thursday that it has received a Notice of Allowance of a US patent application for using novel therapeutic peptide for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage.
RegeneRx Receives Notice of Allowance from U.S. Patent Office for Treatment and Prevention of Neuro and Muscular Degenerative Diseases
Business Wire - Thu Jan 16, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance of a U.S. patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage. The patent will expire in 2026.
RegeneRx Biopharmaceuticals Inc awarded orphan drug designation for TB4 for treating Neurotrophic Keratopathy in the US
M2 - Mon Jan 06, 4:56AM CST
Novel therapeutic peptide developer RegeneRx Biopharmaceuticals Inc (OTC Markets:RGRX) reported on Friday the receipt of the orphan drug designation for its drug candidate, Thymosin beta 4 (T?4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium, in the US.
RegeneRx Receives Orphan Drug Designation for TB4 in the Treatment of Neurotrophic Keratopathy
Business Wire - Fri Jan 03, 7:21AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 (TB4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium (the outside layer of the eye). A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision. The designation, for novel drugs to treat diseases with a prevalence of less than 200,000 patients in the U.S., provides seven years of extended marketing exclusivity, waiver of FDA user fees, tax credits of up to 50% of qualified clinical trial expenses, and eligibility of FDA research grants for clinical trials.
RegeneRx Biopharmaceuticals Inc secures Notice of Allowance for reversal of skin aging product in Canada
M2 - Mon Dec 23, 7:26AM CST
RegeneRx Biopharmaceuticals Inc (Other OTC:RGRX) reported on Friday the receipt of a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (T?4) and various fragments and other related peptides for inhibiting or reversing skin aging.
RegeneRx Receives Notice of Allowance from Canadian Patent Office for Reversal of Skin Aging
Business Wire - Fri Dec 20, 11:01AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for inhibiting or reversing skin aging. The patent will expire in 2021.
RegeneRx Releases Results of Phase 2 Clinical Trial on Patients with Epidermolysis Bullosa
Business Wire - Mon Jun 24, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced results from its dose-escalating, double-blind, placebo-controlled Phase 2 clinical trial in 30 patients with dystrophic and junctional epidermolysis bullosa (EB), a severe "orphan" skin disorder with limited prevalence in the U.S. and Europe. RGN-137 (a topical formulation of Thymosin beta 4 or TB4) was administered to a single non-healing index lesion in these patients daily for 56 days and followed for an additional 14 days post-treatment.
Global Epidermolysis Bullosa - Pipeline Review Report, H1 2013
M2 - Fri Jun 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrf76c/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2013" report to their offering. 'Epidermolysis Bullosa - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa. Scope - A snapshot of the global therapeutic scenario for Epidermolysis Bullosa. - A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis
Skin Ulcers - Pipeline Review, H1 2013: A Feature on Pipeline Projects On the Basis of Monotherapy and Combined Therapeutics
M2 - Tue Jun 04, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gd363b/skin_ulcers) has announced the addition of the "Skin Ulcers - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Skin Ulcers - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Ulcers. Skin Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Skin Ulcers. - A review of the Skin Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - Coverage of the Skin Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Nanotherapeutics, Inc. - Henry Ford Health System - Galderma S.A. - RegeneRx Biopharmaceuticals, Inc. - EyeGene, Inc. For more information visit http://www.researchandmarkets.com/research/gd...kin_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
RegeneRx Issues Letter to Sharholders
Business Wire - Mon May 13, 12:30PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today issued a letter to shareholders describing its future plans and initiatives. The letter may be viewed on RegeneRx's home page or by following this link: http://www.regenerx.com/pdf/Letter-to-Shareho..._Final.pdf
RegeneRx Biopharmaceuticals Inc receives USD225,000 through issuance of convertible note
M2 - Tue Apr 02, 4:33AM CDT
Therapeutic peptide company RegeneRx Biopharmaceuticals Inc (OTC BB:RGRX) reported on Monday the receipt of USD225,000 through the issuance of unsecured convertible notes to two directors and two unaffiliated investors.
RegeneRx Issues $225,000 Convertible Note
Business Wire - Mon Apr 01, 10:39AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced that it has received $225,000 through the issuance of unsecured convertible notes to two directors and two unaffiliated investors. The loan proceeds will allow the Company to maintain current operations and continue work on several opportunities related to its ophthalmic, cardiac and central nervous system drug candidates, as well as certain strategic financial opportunities.
RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
Business Wire - Fri Mar 08, 10:03AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office claiming compositions and methods for treating, preventing, inhibiting, reducing, or repairing tissue deterioration, injury or damage due to heart failure using Thymosin beta 4 (TB4), its isoforms and fragments, derivatives and analogs. The patent is projected to expire in July 2026. The Company holds similar patents issued recently in the US, EU and China.
RegeneRx Biopharmaceuticals Inc awarded Notice of Allowance for treatment of heart diseases in patients in China
M2 - Fri Feb 08, 9:20AM CST
Novel therapeutic peptide company RegeneRx Biopharmaceuticals Inc (OTC Markets:RGRX) reported on Thursday the receipt of a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease.
RegeneRx Receives Notice of Allowance from Chinese Patent Office for Treatment and Prevention of Heart Disease
Business Wire - Thu Feb 07, 1:20PM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease. Claims also include uses for restoring heart tissue in those subjects. The patent will expire July 26, 2026.
Eye Infections - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/nr9wrq/eye_infections) has announced the addition of Global Markets Direct's new report "Eye Infections - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Eye Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eye Infections. Eye Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Eye Infections. - A review of the Eye Infections products under development by companies and universities/research institutes ba
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements
Business Wire - Fri Mar 07, 6:57AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) ("the Company" or "RegeneRx") today announced that it has entered into two product license agreements with Digital Aria Co., Ltd., headquartered in Gyeonggi-do, Korea, for Digital Aria to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. Digital Aria will also make an equity investment into RegeneRx of $2.35 million enabling RegeneRx to move forward with its ophthalmic clinical program, and retains a 10-month option to purchase additional common stock for $825,000.
RegeneRx Biopharmaceuticals wins patent for Thymosin beta 4 for treating Dry Eye Syndrome in Israel
M2 - Tue Feb 25, 5:44AM CST
Biopharmaceutical company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Monday the receipt of patent for Thymosin beta 4 in Israel.
RegeneRx Receives Israeli Patent for Treatment of Dry Eye Syndrome
Business Wire - Mon Feb 24, 9:00AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received an Israeli patent for the treatment of Dry Eye Syndrome using Thymosin beta 4 (TB4) and various fragments of TB4, as well as other analogues and derivatives. The patent will expire in 2026.
RegeneRx Biopharmaceuticals Inc awarded patent allowance in the US for neuro and muscular degenerative diseases
M2 - Fri Jan 17, 10:38AM CST
RegeneRx Biopharmaceuticals Inc (RGRX) revealed on Thursday that it has received a Notice of Allowance of a US patent application for using novel therapeutic peptide for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage.
RegeneRx Receives Notice of Allowance from U.S. Patent Office for Treatment and Prevention of Neuro and Muscular Degenerative Diseases
Business Wire - Thu Jan 16, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance of a U.S. patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage. The patent will expire in 2026.
RegeneRx Biopharmaceuticals Inc awarded orphan drug designation for TB4 for treating Neurotrophic Keratopathy in the US
M2 - Mon Jan 06, 4:56AM CST
Novel therapeutic peptide developer RegeneRx Biopharmaceuticals Inc (OTC Markets:RGRX) reported on Friday the receipt of the orphan drug designation for its drug candidate, Thymosin beta 4 (T?4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium, in the US.
RegeneRx Receives Orphan Drug Designation for TB4 in the Treatment of Neurotrophic Keratopathy
Business Wire - Fri Jan 03, 7:21AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 (TB4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium (the outside layer of the eye). A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision. The designation, for novel drugs to treat diseases with a prevalence of less than 200,000 patients in the U.S., provides seven years of extended marketing exclusivity, waiver of FDA user fees, tax credits of up to 50% of qualified clinical trial expenses, and eligibility of FDA research grants for clinical trials.
RegeneRx Biopharmaceuticals Inc secures Notice of Allowance for reversal of skin aging product in Canada
M2 - Mon Dec 23, 7:26AM CST
RegeneRx Biopharmaceuticals Inc (Other OTC:RGRX) reported on Friday the receipt of a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (T?4) and various fragments and other related peptides for inhibiting or reversing skin aging.
RegeneRx Receives Notice of Allowance from Canadian Patent Office for Reversal of Skin Aging
Business Wire - Fri Dec 20, 11:01AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for inhibiting or reversing skin aging. The patent will expire in 2021.
RegeneRx Releases Results of Phase 2 Clinical Trial on Patients with Epidermolysis Bullosa
Business Wire - Mon Jun 24, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced results from its dose-escalating, double-blind, placebo-controlled Phase 2 clinical trial in 30 patients with dystrophic and junctional epidermolysis bullosa (EB), a severe "orphan" skin disorder with limited prevalence in the U.S. and Europe. RGN-137 (a topical formulation of Thymosin beta 4 or TB4) was administered to a single non-healing index lesion in these patients daily for 56 days and followed for an additional 14 days post-treatment.
Global Epidermolysis Bullosa - Pipeline Review Report, H1 2013
M2 - Fri Jun 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrf76c/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2013" report to their offering. 'Epidermolysis Bullosa - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa. Scope - A snapshot of the global therapeutic scenario for Epidermolysis Bullosa. - A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis
Skin Ulcers - Pipeline Review, H1 2013: A Feature on Pipeline Projects On the Basis of Monotherapy and Combined Therapeutics
M2 - Tue Jun 04, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gd363b/skin_ulcers) has announced the addition of the "Skin Ulcers - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Skin Ulcers - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Ulcers. Skin Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Skin Ulcers. - A review of the Skin Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - Coverage of the Skin Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Nanotherapeutics, Inc. - Henry Ford Health System - Galderma S.A. - RegeneRx Biopharmaceuticals, Inc. - EyeGene, Inc. For more information visit http://www.researchandmarkets.com/research/gd...kin_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
RegeneRx Issues Letter to Sharholders
Business Wire - Mon May 13, 12:30PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today issued a letter to shareholders describing its future plans and initiatives. The letter may be viewed on RegeneRx's home page or by following this link: http://www.regenerx.com/pdf/Letter-to-Shareho..._Final.pdf
RegeneRx Biopharmaceuticals Inc receives USD225,000 through issuance of convertible note
M2 - Tue Apr 02, 4:33AM CDT
Therapeutic peptide company RegeneRx Biopharmaceuticals Inc (OTC BB:RGRX) reported on Monday the receipt of USD225,000 through the issuance of unsecured convertible notes to two directors and two unaffiliated investors.
RegeneRx Issues $225,000 Convertible Note
Business Wire - Mon Apr 01, 10:39AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced that it has received $225,000 through the issuance of unsecured convertible notes to two directors and two unaffiliated investors. The loan proceeds will allow the Company to maintain current operations and continue work on several opportunities related to its ophthalmic, cardiac and central nervous system drug candidates, as well as certain strategic financial opportunities.
RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
Business Wire - Fri Mar 08, 10:03AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office claiming compositions and methods for treating, preventing, inhibiting, reducing, or repairing tissue deterioration, injury or damage due to heart failure using Thymosin beta 4 (TB4), its isoforms and fragments, derivatives and analogs. The patent is projected to expire in July 2026. The Company holds similar patents issued recently in the US, EU and China.
RegeneRx Biopharmaceuticals Inc awarded Notice of Allowance for treatment of heart diseases in patients in China
M2 - Fri Feb 08, 9:20AM CST
Novel therapeutic peptide company RegeneRx Biopharmaceuticals Inc (OTC Markets:RGRX) reported on Thursday the receipt of a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease.
RegeneRx Receives Notice of Allowance from Chinese Patent Office for Treatment and Prevention of Heart Disease
Business Wire - Thu Feb 07, 1:20PM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease. Claims also include uses for restoring heart tissue in those subjects. The patent will expire July 26, 2026.
Eye Infections - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/nr9wrq/eye_infections) has announced the addition of Global Markets Direct's new report "Eye Infections - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Eye Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eye Infections. Eye Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Eye Infections. - A review of the Eye Infections products under development by companies and universities/research institutes ba
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
